| Abstrakt: |
As a result, biological therapies targeting cytokines including tumour necrosis factor inhibitors (e.g. adalimumab, etanercept and infliximab), interleukin (IL) 12 and IL 23 (ustekinumab), and IL -17A (secukinumab) have been licensed internationally for the treatment of psoriasis. Many scientists dedicate their lives to and focus their research on deepening their understanding or developing a potential treatment for a condition. 1986; 115 (4): 421 - 9. 51 Holick MF, Pochi P, Bhawan J. Topically applied and orally-administered 1, 25-dihydroxyvitamin-D3 is a novel, safe, and effective therapy for the treatment of psoriasis-a 3-year experience with histologic analysis. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. [Extracted from the article] |
Plný text